# Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

> **NCT03100877** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Plasma Cell Leukemia in Remission
- Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **PROCEDURE:** pheresis
- **DRUG:** Melphalan
- **BIOLOGICAL:** Palifermin
- **RADIATION:** Total Marrow Irradiation

## Key facts

- **NCT ID:** NCT03100877
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2020-05-24
- **Final completion:** 2020-05-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Feasibility Issues
- **Last updated:** 2017-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100877, "Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03100877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*